Beximco Pharmaceuticals Limited has recently begun its second drug, Sotalol Hydrochloride, export to the US after the successful launch of Carvedilol in August 2016.
The first consignment of Sotalol Hydrochloride was delivered on 29 October 2017 to be distributed through Beximco’s existing partner in the US.
The newest addition to the export basket of Beximco to US in the first quarter of 2017-18 fiscal year is expected to bring further growth in the total earnings of the company.
Over the course of 11 years, Beximco has consistently experienced growth in its annual revenue as shown in the chart.
Total sales for the year 2016-17 is TK 12.18 billion higher than it was in 2005. From 2014 to 2015, there was a growth of 15.7 per cent and highest growth of 33.3 per cent was recorded from 2009 to 2010.
The export data also shows a rising trend with the exception of 2014 when the company experienced a decline of 25.5 per cent.
From 2014 to 2015, the company had the highest growth in export of 68.4 per cent. Total export of the company for the year 2016-17 is Tk 0.989 billion higher than it was in the year 2005.
Source: Latest news from Beximco Pharma’s website and published annual reports.
© 2017 - All Rights with The Financial Express